![](https://endpts.com/wp-content/uploads/2024/05/AstraZeneca-Investor-Day-feature.jpg)
AstraZeneca CFO Aradhana Sarin (L) and CEO Pascal Soriot at the company's investor day (Ayisha Sharma for Endpoints News)
AstraZeneca counts on ‘difficult-to-copy’ therapies for big 2030 goal and beyond
CAMBRIDGE, UK — Pascal Soriot has set an ambitious $80 billion revenue target for AstraZeneca by 2030. But he’s not stopping there. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.